PE20181167A1 - Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih - Google Patents

Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih

Info

Publication number
PE20181167A1
PE20181167A1 PE2018000603A PE2018000603A PE20181167A1 PE 20181167 A1 PE20181167 A1 PE 20181167A1 PE 2018000603 A PE2018000603 A PE 2018000603A PE 2018000603 A PE2018000603 A PE 2018000603A PE 20181167 A1 PE20181167 A1 PE 20181167A1
Authority
PE
Peru
Prior art keywords
chain
immunoglobulin
prevention
triespecific
treatment
Prior art date
Application number
PE2018000603A
Other languages
English (en)
Spanish (es)
Inventor
Zhi-Yong Yang
Gary J Nabel
Ling Xu
Ronnie Wei
Huawei Qiu
Jochen Beninga
Jochen Kruip
Ercole Rao
Wulf-Dirk Leuschner
Christian Beil
Christian Lange
Mark Connors
John R Mascola
Richard A Koup
Jinghe Huang
Nicole A Doria-Rose
Tongqing Zhou
Peter D Kwong
Young Do Kwon
Amarendra Pegu
Mangaiarkarasi Asokan
Original Assignee
Sanofi Sa
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Us Health filed Critical Sanofi Sa
Publication of PE20181167A1 publication Critical patent/PE20181167A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PE2018000603A 2015-10-25 2016-10-24 Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih PE20181167A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US201662331169P 2016-05-03 2016-05-03

Publications (1)

Publication Number Publication Date
PE20181167A1 true PE20181167A1 (es) 2018-07-19

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000603A PE20181167A1 (es) 2015-10-25 2016-10-24 Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih

Country Status (30)

Country Link
US (4) US20190054182A1 (https=)
EP (2) EP3365366B1 (https=)
JP (3) JP7169190B2 (https=)
KR (1) KR102687212B1 (https=)
CN (4) CN117069855A (https=)
AR (1) AR106466A1 (https=)
AU (2) AU2016347058B2 (https=)
BR (1) BR112018008011A2 (https=)
CA (1) CA3002664A1 (https=)
CL (1) CL2018001065A1 (https=)
CO (1) CO2018005337A2 (https=)
CR (1) CR20180288A (https=)
DO (1) DOP2018000102A (https=)
EA (1) EA201891028A1 (https=)
ES (1) ES2894304T3 (https=)
HR (1) HRP20211528T1 (https=)
HU (1) HUE056608T2 (https=)
IL (2) IL301140A (https=)
MA (1) MA42641A1 (https=)
MX (2) MX2018005048A (https=)
MY (1) MY192278A (https=)
PE (1) PE20181167A1 (https=)
PH (1) PH12018500873A1 (https=)
PL (1) PL3365366T3 (https=)
RS (1) RS62437B1 (https=)
SG (1) SG11201803324VA (https=)
SI (1) SI3365366T1 (https=)
TW (3) TW202442675A (https=)
UY (1) UY36965A (https=)
WO (1) WO2017074878A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
US10519222B2 (en) * 2014-02-28 2019-12-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region
HRP20211528T1 (hr) 2015-10-25 2021-12-24 Sanofi Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
EP3371214A1 (en) 2015-11-03 2018-09-12 THE UNITED STATES OF AMERICA, represented by the S Neutralizing antibodies to hiv-1 gp41 and their use
IL262241B2 (en) * 2016-04-13 2024-05-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
HRP20231188T1 (hr) * 2016-04-13 2024-02-02 Sanofi Trispecifični i/ili trovalentni vezujući proteini
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
WO2018183294A1 (en) * 2017-03-27 2018-10-04 David Weiner Dna antibody constructs for use against hiv
JP7009517B2 (ja) * 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
CA3078800A1 (en) 2017-10-10 2019-04-18 Sanofi Anti-cd38 antibodies and methods of use
JP2021507717A (ja) * 2017-12-18 2021-02-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ 抗原結合性ポリペプチド
EP3728311A4 (en) * 2017-12-21 2021-11-17 The Trustees of Columbia University in the City of New York BIS SPECIFIC HIV-1 NEUTRALIZING ANTIBODIES
WO2019140320A1 (en) 2018-01-12 2019-07-18 Genzyme Corporation Methods for the quantitation of polypeptides
US11845788B2 (en) 2018-05-22 2023-12-19 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (HIV)
CA3115679A1 (en) * 2018-10-09 2020-04-16 Sanofi Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
WO2020106713A1 (en) * 2018-11-21 2020-05-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
TW202104274A (zh) 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
PH12021500041A1 (en) * 2019-04-09 2022-06-06 Sanofi Sa Trispecific binding proteins, methods, and uses thereof
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
US20210123926A1 (en) 2019-10-25 2021-04-29 Sanofi Methods for analyzing chain mispairing in multispecific binding proteins
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
US12195524B2 (en) * 2020-08-25 2025-01-14 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
CN118591388A (zh) * 2021-09-29 2024-09-03 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
TW202330595A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118660907A (zh) * 2021-09-29 2024-09-17 摩德斯医疗股份有限公司 用于hiv的抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2025108551A1 (en) 2023-11-23 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025109206A1 (en) 2023-11-22 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
US20250376537A1 (en) 2024-05-17 2025-12-11 Sanofi Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
AU2002241922B2 (en) 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
AU2010298025B2 (en) 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
EP2638072A4 (en) 2010-11-12 2014-05-07 Univ Rockefeller FUSION PROTEINS FOR HIV THERAPY
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI588156B (zh) * 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EA032929B1 (ru) * 2011-05-17 2019-08-30 Дзе Рокфеллер Юниверсити Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
CA2854806A1 (en) * 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
BR112014010823B1 (pt) 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CA2886036A1 (en) * 2012-09-25 2014-04-03 Ichnos Sciences SA Purification of hetero-dimeric immunoglobulins
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
CA2889723A1 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
MX375359B (es) 2013-02-26 2025-03-06 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de células t.
TW201446800A (zh) 2013-03-15 2014-12-16 Abbvie Inc 針對ＴＮＦα之雙特異性結合蛋白
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CA2954168C (en) 2013-08-02 2023-09-19 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
CN110627907B (zh) 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
BR112017004270B1 (pt) 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
CR20170383A (es) 2015-01-23 2017-11-22 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CA2986237A1 (en) 2015-05-20 2016-11-24 Quantum-Si Incorporated Method of determining the sequence of a nucleic acid using time resolved luminescence
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
WO2017053556A1 (en) 2015-09-22 2017-03-30 The Trustees Of The University Of Pennsylvania Method of redirecting t cells to treat hiv infection
HRP20211528T1 (hr) 2015-10-25 2021-12-24 Sanofi Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
UA125819C2 (uk) 2015-12-15 2022-06-15 Гіліад Сайєнсіз, Інк. ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, ЩО ЗВ'ЯЗУЄТЬСЯ З gp120 ВІРУСУ ІМУНОДЕФІЦИТУ ЛЮДИНИ
IL262241B2 (en) 2016-04-13 2024-05-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
HRP20231188T1 (hr) 2016-04-13 2024-02-02 Sanofi Trispecifični i/ili trovalentni vezujući proteini
EP3575319A4 (en) 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018183294A1 (en) 2017-03-27 2018-10-04 David Weiner Dna antibody constructs for use against hiv
CA3078800A1 (en) 2017-10-10 2019-04-18 Sanofi Anti-cd38 antibodies and methods of use
CA3115679A1 (en) 2018-10-09 2020-04-16 Sanofi Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
JP2021072847A (ja) 2021-05-13
US20220226495A1 (en) 2022-07-21
US20200054765A1 (en) 2020-02-20
MA42641A1 (fr) 2019-03-29
NZ742825A (en) 2024-04-26
KR102687212B1 (ko) 2024-07-19
US11129905B2 (en) 2021-09-28
EP3365366A1 (en) 2018-08-29
EP3819310A1 (en) 2021-05-12
HUE056608T2 (hu) 2022-02-28
IL301140A (en) 2023-05-01
EA201891028A1 (ru) 2019-02-28
JP7724814B2 (ja) 2025-08-18
JP7328267B2 (ja) 2023-08-16
CN109311966B (zh) 2023-03-10
JP7169190B2 (ja) 2022-11-10
US20250312475A1 (en) 2025-10-09
PL3365366T3 (pl) 2022-01-31
CO2018005337A2 (es) 2018-07-10
MX2018005048A (es) 2018-09-06
RS62437B1 (sr) 2021-11-30
TWI750139B (zh) 2021-12-21
MX2022014631A (es) 2023-01-11
AU2024200395A1 (en) 2024-04-11
IL258822B1 (en) 2023-04-01
KR20180063336A (ko) 2018-06-11
ES2894304T3 (es) 2022-02-14
CN116789841A (zh) 2023-09-22
JP2023085476A (ja) 2023-06-20
WO2017074878A8 (en) 2018-05-24
HK1253385A1 (zh) 2019-06-14
CN116675776A (zh) 2023-09-01
IL258822B2 (en) 2023-08-01
TW202219064A (zh) 2022-05-16
TW201730210A (zh) 2017-09-01
BR112018008011A2 (en) 2018-10-30
HRP20211528T1 (hr) 2021-12-24
US20190054182A1 (en) 2019-02-21
IL258822A (en) 2018-06-28
AR106466A1 (es) 2018-01-17
CL2018001065A1 (es) 2018-11-23
WO2017074878A1 (en) 2017-05-04
EP3365366B1 (en) 2021-07-14
AU2016347058B2 (en) 2023-11-09
US11779651B2 (en) 2023-10-10
UY36965A (es) 2017-05-31
DOP2018000102A (es) 2018-11-30
AU2016347058A1 (en) 2018-06-14
TW202442675A (zh) 2024-11-01
MY192278A (en) 2022-08-16
CN109311966A (zh) 2019-02-05
CA3002664A1 (en) 2017-05-04
SG11201803324VA (en) 2018-05-30
JP2018537966A (ja) 2018-12-27
PH12018500873A1 (en) 2018-11-12
NZ781602A (en) 2025-07-25
SI3365366T1 (sl) 2022-02-28
CR20180288A (es) 2018-09-11
CN117069855A (zh) 2023-11-17

Similar Documents

Publication Publication Date Title
PE20181167A1 (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20190737A1 (es) Anticuerpos anti-cd27
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
ECSP17005649A (es) Anticuerpos anti-tau humanizados
EA202192736A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с псма
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
PE20170767A1 (es) Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
EA201890447A1 (ru) Гуманизированные антитела к рецептору ccr7
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
AR105267A1 (es) Anticuerpos de unión a tau
CO2020002060A2 (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201991729A1 (ru) Антитела к tgf-бета и их применение
EA202192810A1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201992206A1 (ru) Моноклональное антитело к pd-l1